Evaluation of the linearity of docetaxel pharmacokinetics

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 2, 1998, Pages 155-159

  McLeod, Howard L ^a   Kearns, Christine M ^b   Kuhn, John G ^c   Bruno, Rene ^d  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d SANOFI   (France)

Author keywords

Docetaxel; Michaelis Menten processes; Paclitaxel; Pharmacokinetics

Indexed keywords

DOCETAXEL; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; COMPARTMENT MODEL; CONTROLLED STUDY; CURVE FITTING; DOSE RESPONSE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MICHAELIS CONSTANT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS, PHASE I; HUMANS; NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 0031833541     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050799     Document Type: Article

References (19)

1. Aapro MS, Zulian G, Alberto P, Bruno R, Oulid-Aissa D, Le Bail N (1992) Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of Taxotere. Ann Oncol 3: 53
2. Akaike H (1976) An information criterion (AIC). Math Sci 14: 5
3. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. I. Preclinical experience. Anticancer Drugs 6: 339
4. Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, LeBail N, Kaye SB, Kerr DJ (1993) Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53: 523
5. Bruno R, Vivier N. Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24: 153
6. Bruno R, Hille D, Riva A, Vivier N, Bokkel Huinink WW ten, Oosterom AT van, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies. J Clin Oncol 16: 187
7. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss G, Eckardt J, Rodriguez G, Rinaldi D, Wall J, Cook G, Smith S, Vreeland F, Bayssas M, LeBail N, Von Hoff D (1993) Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 11: 950
8. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314
9. D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Prog Biomed 9: 115
10. Extra J-M, Rousseau F, Bruno R, Clavel M, LeBail M, Marty M (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53: 1037
11. Kearns CM, Giani L, Egorin MJ (1995) Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22 [Suppl 6]: 16
12. Launay Iliadis MC, Bruno R, Cosson V, Vergniol JC, Oulid Aissa D, Marty M, Clavel M, Aapro M, Le Bail N, Iliadis A (1995) Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed effect modeling and nonparametric maximum likelihood estimation. Cancer Chemother Pharmacol 37: 47
13. Marre F, Sanderink G-J, Sousa G de, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56: 1296
14. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW (1994) Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54: 5543
15. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV (1994) Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12: 532
16. Sparreboom A, Tellingen O van, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112
17. Vergniol JC, Bruno R, Montay G, Frydman A (1992) Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582: 273
18. Verweij J (1994) Docetaxel (Taxotere): a new anti-cancer drug with promising potential? Br J Cancer 70: 183
19. Verweij J, Clavel M, Chevallier B (1994) Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5: 495